Bal Pharma Limited Announces Q1 Results, Director Changes, and Philippine Joint Venture Investment

Bal Pharma Limited Announces Q1 Results, Director Changes, and Philippine Joint Venture Investment​

Bal Pharma Limited, during a recent Board meeting held on August 12, 2026, approved key strategic decisions including changes in director designations, an investment into a proposed joint venture entity in the Philippines, and the preferential allotment of warrants to its promoter. The company also released its unaudited financial results for the quarter ended June 30, 2026.

The Board meeting reviewed and sanctioned both the consolidated and standalone unaudited financial results for the quarter ended on June 30, 2026, which included a limited review report from statutory auditors with an unmodified opinion.

Strategic Appointments and Investment​

Among the board decisions was approving changes in director designations effective from October 1, 2026. Mr. Ravindra Kumar Kothari transitioned from Non-Executive Director to Whole-Time Director (Executive Director), while Mr. Virupakshaya Himesh changed designation from Whole-Time Director to Non-Executive Director. Both changes are subject to approval by the members at the upcoming Annual General Meeting.

The company also approved a proposal for an investment in a planned Joint Venture entity to be established in the Republic of the Philippines. The investment limit is set up to INR 9 Crores, pending compliance with applicable laws and regulations.

Promoter Warrants Allotment​

Additionally, the Board approved the allotment of 10,00,000 warrants on a preferential basis to Mr. Shailesh Siroya, Promoter of the Company. The allocation was executed at an issue price of ₹84 per warrant, totaling ₹8,40,00,000/- (Rupees Eight Crore Forty Lakhs only).

The company has already received 25% of the issue price against these warrants, amounting to ₹2,10,00,000/- (Rupees Two Crore Ten Lakhs only). Each warrant is convertible into one fully paid-up Equity Share having a face value of ₹10 each. The remaining balance must be paid within 18 months from the date of allotment.

Financial Performance Snapshot​

The unaudited financial results for the quarter ended June 30, 2026, showed the company's performance across various metrics.

Standalone Results (Quarter Ended June 30, 2026) in Rs. Lakhs:


Consolidated Results (Quarter Ended June 30, 2026) in Rs. Lakhs:

Joint Venture Entity Details​

The planned joint venture entity in the Philippines will be focused on registration, importation, commercialization, distribution, and sale of designated pharmaceutical products. The JV involves Bal Pharma Limited ("Manufacturer") and Hemera International Private Limited ("Supply Chain Partner"). Bal Pharma Limited holds a 65% stake while Hemera Holdings Pte Limited holds 35%.

The investment is intended to establish a structured collaboration for market penetration in the Philippines, with potential subsequent expansion into other ASEAN markets.

BALPHARMA Stock Price Movement​

Today, Bal Pharma Limited shares surged to close at ₹90.50 after gaining 4.54%. The stock traded within an intraday range of ₹86.04 and ₹91.50, with a total volume of 34,146 shares recorded during the session.